Document Detail

Molecular profiling of docetaxel cytotoxicity in breast cancer cells: uncoupling of aberrant mitosis and apoptosis.
MedLine Citation:
PMID:  17099726     Owner:  NLM     Status:  MEDLINE    
Among microtubule-targeting agents, docetaxel has received recent interest owing to its good therapeutic index. Clinical trials have underlined its potential for the treatment of advanced breast cancer, although little is known about its molecular mode of action in this context. We characterized the molecular changes induced by docetaxel in two well-known human breast carcinoma cell lines. Two mechanisms of action according to drug concentration were suggested by a biphasic sensitivity curve, and were further validated by cell morphology, cell cycle and cell death changes. Two to four nanomolar docetaxel induced aberrant mitosis followed by late necrosis, and 100 nM docetaxel induced mitotic arrest followed by apoptosis. Passing through mitosis phase was a requirement for hypodiploidy to occur, as shown by functional studies in synchronized cells and by combining docetaxel with the proteasome inhibitor MG132. Transcriptional profiling showed differences according to cell line and docetaxel concentration, with cell cycle, cell death and structural genes commonly regulated in both cell lines. Although p53 targets were mainly induced with low concentration of drug in MCF7 cells, its relevance in the dual mechanism of docetaxel cytotoxicity was ruled out by using an isogenic shp53 cell line. Many of the genes shown in this study may contribute to the dual mechanism by which docetaxel inhibits the growth of breast cancer cells at different concentrations. These findings provide a basis for rationally enhancing docetaxel therapy, considering lower concentrations, and better drug combinations.
H Hernández-Vargas; J Palacios; G Moreno-Bueno
Related Documents :
12199376 - Growth and cell cycle regulation by isoflavones in human breast carcinoma cells.
18804536 - Simvastatin inhibits cell cycle progression in glucose-stimulated proliferation of aort...
15077166 - Cyr61 suppresses the growth of non-small-cell lung cancer cells via the beta-catenin-c-...
9257696 - Cell cycle specificity of fas-mediated apoptosis in wil-2 cells.
20516476 - Ammonia: a diffusible factor released by proliferating cells that induces autophagy.
17022806 - Activation of chloride transport in cf airway epithelial cell lines and primary cf nasa...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2006-11-13
Journal Detail:
Title:  Oncogene     Volume:  26     ISSN:  0950-9232     ISO Abbreviation:  Oncogene     Publication Date:  2007 May 
Date Detail:
Created Date:  2007-05-03     Completed Date:  2007-06-20     Revised Date:  2013-05-28    
Medline Journal Info:
Nlm Unique ID:  8711562     Medline TA:  Oncogene     Country:  England    
Other Details:
Languages:  eng     Pagination:  2902-13     Citation Subset:  IM    
Breast and Gynaecological Cancer Group, Molecular Pathology Programme, Spanish National Cancer Centre (CNIO), Madrid, Spain.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Agents / pharmacology
Apoptosis / drug effects*,  genetics
Breast Neoplasms / genetics*,  pathology
Carcinoma / genetics*,  pathology
Cell Cycle / drug effects,  genetics
Cell Proliferation / drug effects
Dose-Response Relationship, Drug
Gene Expression Profiling
Gene Expression Regulation, Neoplastic / drug effects*
Mitosis / drug effects*,  genetics
Taxoids / pharmacology*
Tumor Cells, Cultured
Reg. No./Substance:
0/Antineoplastic Agents; 0/Taxoids; 15H5577CQD/docetaxel

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Ink4c is dispensable for tumor suppression in Myc-induced B-cell lymphomagenesis.
Next Document:  Effect of Akt inhibition on scatter factor-regulated gene expression in DU-145 human prostate cancer...